Abstract
Two New York primary care programs that offer buprenorphine treatment for opioid use disorder (OUD) are reporting dramatically reduced wait times and other benefits from temporarily relaxed restrictions allowing initiation to treatment after a telemedicine visit. Leaders of the programs say persons exiting the criminal justice system and clients of syringe services programs have been among the main beneficiaries of an exception that was enacted to maintain access to care for OUD during the COVID‐19 crisis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
